Cargando…
Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials
BACKGROUND: This study assessed the immunogenicity of pegvaliase (recombinant Anabaena variabilis phenylalanine [Phe] ammonia lyase [PAL] conjugated with polyethylene glycol [PEG]) treatment in adults with phenylketonuria (PKU) and its impact on safety and efficacy. METHODS: Immunogenicity was asses...
Autores principales: | Gupta, Soumi, Lau, Kelly, Harding, Cary O., Shepherd, Gillian, Boyer, Ryan, Atkinson, John P., Knight, Vijaya, Olbertz, Joy, Larimore, Kevin, Gu, Zhonghu, Li, Mingjin, Rosen, Orli, Zoog, Stephen J., Weng, Haoling H., Schweighardt, Becky |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286649/ https://www.ncbi.nlm.nih.gov/pubmed/30366815 http://dx.doi.org/10.1016/j.ebiom.2018.10.038 |
Ejemplares similares
-
Pharmacokinetic, pharmacodynamic, and immunogenic rationale for optimal dosing of pegvaliase, a PEGylated bacterial enzyme, in adult patients with phenylketonuria
por: Qi, Yulan, et al.
Publicado: (2021) -
Evidence- and consensus-based recommendations for the use of
pegvaliase in adults with phenylketonuria
por: Longo, Nicola, et al.
Publicado: (2018) -
Long-term safety and efficacy of pegvaliase for the treatment of phenylketonuria in adults: combined phase 2 outcomes through PAL-003 extension study
por: Longo, Nicola, et al.
Publicado: (2018) -
Long-term comparative effectiveness of pegvaliase versus standard of care comparators in adults with phenylketonuria
por: Zori, Roberto, et al.
Publicado: (2019) -
A benefit-risk analysis of pegvaliase for the treatment of phenylketonuria: A study of patients' preferences
por: Sri Bhashyam, Sumitra, et al.
Publicado: (2019)